Tags

Type your tag names separated by a space and hit enter

Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
Eur Child Adolesc Psychiatry. 2006 Mar; 15(2):105-10.EC

Abstract

OBJECTIVE

To examine the influence of comorbid oppositional defiant disorder (ODD) on the relative risk (RR) of relapse during 9 months of treatment with atomoxetine for attention-deficit/hyperactivity disorder (ADHD).

METHOD

Four hundred and sixteen children and adolescents with ADHD whose symptoms remitted during initial 10-week, open-label atomoxetine treatment were randomly assigned to continue with atomoxetine or placebo.

RESULTS

In all, 43% met criteria for comorbid ODD. A total of 17% of patients with comorbid ODD relapsed (CGI-Severity score >or= 3 and ADHD Rating Scale total score of 90% or more of baseline at study entry on two consecutive visits) during atomoxetine treatment, compared with 26% of patients without comorbid ODD (RR 0.67, 95% CI 0.42-1.06). Mean time to relapse was not significantly different [mean (SE) days to relapse, ADHD/ +ODD: 215 (7.38); ADHD/-ODD: 211 (7.61); log rank p = 0.08]. This finding is placed within the context of atomoxetine affording an overall protection against relapse compared with placebo (RR 0.59, 95% CI 0.43-0.80).

CONCLUSIONS

Comorbid ODD does not influence the rate of relapse of patients with ADHD during longer-term treatment with atomoxetine. Atomoxetine protects against the relapse of ADHD symptoms regardless of the presence or absence of comorbid ODD.

Authors+Show Affiliations

Child and Youth Mental Health Service, University of Newcastle, Locked Bag 1014, Wallsend, NSW 2287, Australia. philip.hazell@hne.health.nsw.gov.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16523251

Citation

Hazell, Philip, et al. "Comorbid Oppositional Defiant Disorder and the Risk of Relapse During 9 Months of Atomoxetine Treatment for Attention-deficit/hyperactivity Disorder." European Child & Adolescent Psychiatry, vol. 15, no. 2, 2006, pp. 105-10.
Hazell P, Zhang S, Wolańczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2006;15(2):105-10.
Hazell, P., Zhang, S., Wolańczyk, T., Barton, J., Johnson, M., Zuddas, A., Danckaerts, M., Ladikos, A., Benn, D., Yoran-Hegesh, R., Zeiner, P., & Michelson, D. (2006). Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. European Child & Adolescent Psychiatry, 15(2), 105-10.
Hazell P, et al. Comorbid Oppositional Defiant Disorder and the Risk of Relapse During 9 Months of Atomoxetine Treatment for Attention-deficit/hyperactivity Disorder. Eur Child Adolesc Psychiatry. 2006;15(2):105-10. PubMed PMID: 16523251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. AU - Hazell,Philip, AU - Zhang,Shuyu, AU - Wolańczyk,Tomasz, AU - Barton,Joanne, AU - Johnson,Mats, AU - Zuddas,Alessandro, AU - Danckaerts,Marina, AU - Ladikos,Andrula, AU - Benn,David, AU - Yoran-Hegesh,Roni, AU - Zeiner,Pal, AU - Michelson,David, PY - 2005/09/09/accepted PY - 2006/3/9/pubmed PY - 2006/8/4/medline PY - 2006/3/9/entrez SP - 105 EP - 10 JF - European child & adolescent psychiatry JO - Eur Child Adolesc Psychiatry VL - 15 IS - 2 N2 - OBJECTIVE: To examine the influence of comorbid oppositional defiant disorder (ODD) on the relative risk (RR) of relapse during 9 months of treatment with atomoxetine for attention-deficit/hyperactivity disorder (ADHD). METHOD: Four hundred and sixteen children and adolescents with ADHD whose symptoms remitted during initial 10-week, open-label atomoxetine treatment were randomly assigned to continue with atomoxetine or placebo. RESULTS: In all, 43% met criteria for comorbid ODD. A total of 17% of patients with comorbid ODD relapsed (CGI-Severity score >or= 3 and ADHD Rating Scale total score of 90% or more of baseline at study entry on two consecutive visits) during atomoxetine treatment, compared with 26% of patients without comorbid ODD (RR 0.67, 95% CI 0.42-1.06). Mean time to relapse was not significantly different [mean (SE) days to relapse, ADHD/ +ODD: 215 (7.38); ADHD/-ODD: 211 (7.61); log rank p = 0.08]. This finding is placed within the context of atomoxetine affording an overall protection against relapse compared with placebo (RR 0.59, 95% CI 0.43-0.80). CONCLUSIONS: Comorbid ODD does not influence the rate of relapse of patients with ADHD during longer-term treatment with atomoxetine. Atomoxetine protects against the relapse of ADHD symptoms regardless of the presence or absence of comorbid ODD. SN - 1018-8827 UR - https://www.unboundmedicine.com/medline/citation/16523251/Comorbid_oppositional_defiant_disorder_and_the_risk_of_relapse_during_9_months_of_atomoxetine_treatment_for_attention_deficit/hyperactivity_disorder_ L2 - https://dx.doi.org/10.1007/s00787-006-0506-y DB - PRIME DP - Unbound Medicine ER -